Helsinki-based pharmaceutical company CurifyLabs has secured €2.5 million in grant funding from the European Innovation Council as part of its acceleration program. The capital will allow further development of its the MiniLab technology, Tech.eu reports.
- Founded in 2021 by Charlotta Topelius and Niklas Sandler Topelius, CurifyLabs is offering new industry level standards to mass customisation of medicines. The company’s technology of improved drug compounding can provide better patient safety and efficacy at significantly lower cost.
- The MiniLab technology is the company’s main offering. It is a smart drug formulation platform, incorporating cutting-edge technology to redefine the drug compounding process.
“We are delighted to have received this prestigious grant from the European Innovation Council to further develop MiniLab and bring a high-quality 3D printing solution for compounding of personalised medicines to pharmacists across Europe,”
Charlotta Topelius, Founder and CEO of CurifyLabs, comments on the deal.
- The MiniLab solution is already successfully piloted by several pharmacies in Finland, Spain, Switzerland, Germany, and the Netherlands.
- CurifyLabs will use the funding to further develop its product.
About EIC Accelerator
The EIC Accelerator was introduced in December, 2022 by the European Commission to support the commercialization of high-risk, high-impact technologies in the European Union. The accelerator supports individual Small and Medium Enterprises (SMEs) with grants of up to €2.5 million and investments of up to €15 million.
